Amphastar Pharmaceuticals, Inc.AMPH stock score: 62/100
$28.11 · -5.39% · Scored Nov 19, 2026
- Technical
- 54
- Fundamental
- 65
- News
- 51
The reading
Amphastar Pharmaceuticals (AMPH) scores 62 out of 100, which reads neutral, higher than 81% of Healthcare stocks and 84% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 65, technicals 54.
Among the fundamentals, Current Ratio at 97 and Free Cash Flow Yield at 97 score highest, while Earnings Growth (Annual) at 1 weighs the most against it.
On the daily chart, trend-following indicators average 58 and contrarian oscillators 41.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 49 to 65, and it is up 10 points over the period.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals (AMPH) is a California-based drugmaker that develops, manufactures and sells generic and branded medicines, focusing on injectable, inhalation and intranasal products. Its branded products include BAQSIMI, a nasal glucagon spray for severe low blood sugar that it acquired from Eli Lilly, and Primatene MIST, an over-the-counter epinephrine inhaler for mild asthma. It also sells hospital injectables such as glucagon, epinephrine, naloxone and enoxaparin. The company has expanded into generic inhalation products, and its pipeline includes a biosimilar version of insulin aspart and generic versions of peptide drugs. Amphastar makes many of its own active ingredients, including insulin, in the United States and China. Customers include drug wholesalers, hospitals, group purchasing organizations and retail pharmacies, and the company earns money from product sales.
Amphastar competes with generic injectable makers such as Fresenius Kabi, Hikma and Pfizer’s Hospira unit, and with companies selling rival glucagon and insulin products such as Novo Nordisk and Xeris Biopharma. Its edge rests on manufacturing complex products that are hard to copy, vertical integration into active ingredients and a mix of branded and generic medicines. Investors who follow AMPH stock tend to watch sales of BAQSIMI and Primatene MIST and the impact of pricing pressure on them. Regulatory progress on its biosimilar and generic pipeline is closely followed. New generic competition, drug shortages, manufacturing compliance and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward AMPH’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
65Pulling it up
Current assets divided by current liabilities: the ability to pay short-term bills.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Forward P/E ratio uses estimated future earnings to calculate valuation.
Holding it back
Net income growth from the prior fiscal year to the latest.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Gross margins show profitability after cost of goods sold.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
58Pulling it up
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Performance versus SPY compares the stock's returns to the S&P 500 index.
- SMA 20095
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 34 | 1 |
| Daily | 58 | 3 |
| Weekly | 58 | 2 |
| Monthly | 53 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 62 |
| Nov 18, 2026 | 64 |
| Nov 17, 2026 | 63 |
| Nov 16, 2026 | 63 |
| Nov 15, 2026 | 64 |
| Nov 14, 2026 | 64 |
| Nov 13, 2026 | 64 |
| Nov 12, 2026 | 65 |
| Nov 11, 2026 | 57 |
| Nov 10, 2026 | 58 |
| Nov 7, 2026 | 58 |
| Nov 6, 2026 | 58 |
| Nov 5, 2026 | 58 |
| Nov 4, 2026 | 57 |
| Nov 3, 2026 | 56 |
| Nov 2, 2026 | 56 |
| Nov 1, 2026 | 57 |
| Oct 30, 2026 | 57 |
| Oct 29, 2026 | 56 |
| Oct 28, 2026 | 55 |
| Oct 27, 2026 | 54 |
| Oct 26, 2026 | 53 |
| Oct 25, 2026 | 52 |
| Oct 24, 2026 | 52 |
| Oct 23, 2026 | 51 |
| Oct 22, 2026 | 55 |
| Oct 21, 2026 | 55 |
| Oct 20, 2026 | 54 |
| Oct 19, 2026 | 55 |
| Oct 18, 2026 | 55 |
| Oct 17, 2026 | 55 |
| Oct 16, 2026 | 55 |
| Oct 15, 2026 | 56 |
| Oct 14, 2026 | 55 |
| Oct 13, 2026 | 56 |
| Oct 12, 2026 | 58 |
| Oct 11, 2026 | 57 |
| Oct 10, 2026 | 57 |
| Oct 9, 2026 | 57 |
| Oct 8, 2026 | 56 |
| Oct 7, 2026 | 55 |
| Oct 6, 2026 | 56 |
| Oct 5, 2026 | 55 |
| Oct 4, 2026 | 55 |
| Oct 3, 2026 | 55 |
| Oct 2, 2026 | 55 |
| Oct 1, 2026 | 54 |
| Sep 30, 2026 | 55 |
| Sep 29, 2026 | 56 |
| Sep 28, 2026 | 57 |
| Sep 27, 2026 | 57 |
| Sep 26, 2026 | 57 |
| Sep 25, 2026 | 57 |
| Sep 24, 2026 | 56 |
| Sep 23, 2026 | 57 |
| Sep 22, 2026 | 55 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 52 |
| Sep 19, 2026 | 52 |
| Sep 18, 2026 | 52 |
| Sep 17, 2026 | 54 |
| Sep 16, 2026 | 55 |
| Sep 15, 2026 | 53 |
| Sep 14, 2026 | 55 |
| Sep 13, 2026 | 54 |
| Sep 12, 2026 | 54 |
| Sep 11, 2026 | 54 |
| Sep 10, 2026 | 53 |
| Sep 9, 2026 | 53 |
| Sep 8, 2026 | 53 |
| Sep 7, 2026 | 52 |
| Sep 6, 2026 | 53 |
| Sep 5, 2026 | 52 |
| Sep 4, 2026 | 54 |
| Sep 2, 2026 | 54 |
| Sep 1, 2026 | 54 |
| Aug 31, 2026 | 52 |
| Aug 30, 2026 | 51 |
| Aug 29, 2026 | 51 |
| Aug 28, 2026 | 52 |
| Aug 27, 2026 | 52 |
| Aug 26, 2026 | 53 |
| Aug 25, 2026 | 52 |
| Aug 24, 2026 | 49 |
| Aug 23, 2026 | 52 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.94
- Risk grade (1–10)
- 7
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| ALVO Alvotech | $1.5B | 55 |
| PCRX Pacira BioSciences | $1.5B | 65 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| HROW Harrow | $1.2B | 57 |
| CRON Cronos Group | $1.1B | 59 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is AMPH's stock rating today?
AMPH scores 62/100 (Neutral) as of Nov 19, 2026: technical 54, fundamental 65, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does Amphastar Pharmaceuticals do?
Amphastar Pharmaceuticals (AMPH) is a California-based drugmaker that develops, manufactures and sells generic and branded medicines, focusing on injectable, inhalation and intranasal products. Its branded products include BAQSIMI, a nasal glucagon spray for severe low blood sugar that it acquired from Eli Lilly, and Primatene MIST, an over-the-counter epinephrine inhaler for mild asthma.
Is AMPH stock a buy?
The score is not a buy or sell recommendation. A 62 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the AMPH score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/amph/"><img src="https://stocksscores.com/stocks/amph/badge.svg" alt="AMPH stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/amph/)